减重手术用于代谢功能障碍相关脂肪性肝病(MASLD):机制认识现状
本文综述减重手术(MBS)治疗代谢功能障碍相关脂肪性肝病(MASLD)的机制与疗效。MASLD影响全球超过30%成人,可从单纯脂肪变进展为脂肪性肝炎、纤维化、肝硬化和肝癌。MBS是III级肥胖及伴合并症II级肥胖的成熟干预手段,可改善肝脏脂肪变、炎症、纤维化并降低癌症风险,其作用可能超越单纯饮食限制,涉及肝脏转录程序改变。
要点
- MASLD影响全球超过30%成人,肥胖是其主要危险因素之一。
- MBS是III级肥胖及伴合并症II级肥胖的成熟干预,可显著且持续减重。
- Roux-en-Y胃旁路术和袖状胃切除术可改善MASLD的脂肪变、炎症、纤维化并降低癌症风险。
核心结论
- MBS可改善MASLD患者的肝脏脂肪变、炎症、纤维化并降低癌症风险,其效应可能超越单纯饮食限制,涉及肝脏转录程序改变。
研究设计与样本
- 综述,总结临床前研究、临床试验及先进生物技术相关证据,聚焦MBS对MASLD的致病与治疗效应。
主要发现
- MASLD影响全球超过30%成人,可从单纯脂肪变进展为脂肪性肝炎(MASH)、纤维化、肝硬化和肝癌。
- 肥胖是MASLD的主要危险因素之一,高效抗肥胖治疗有望阻止MASLD进展。
- 常见MBS术式(如Roux-en-Y胃旁路术和袖状胃切除术)可改善MASLD/MASH患者的肝脏脂肪变、炎症、纤维化并降低癌症风险。
- MBS可诱导肝脏转录程序改变,提示其效应可能超越单纯限制饮食摄入。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver diseases (MASLDs) encompass a spectrum of liver disorders primarily defined by hepatic steatosis and cardiometabolic risk factors. MASLD affects over 30% of the global adult population, representing a substantial risk for public health. MASLD can progress from simple steatosis to steatohepatitis (termed MASH), marked by inflammation and fibrosis, potentially leading to cirrhosis and liver cancer. Obesity has been identified as one of the leading risk factors for MASLD, fueling the concept that efficient anti-obesity therapy will halt MASLD progression. Bariatric surgery (also termed metabolic and bariatric surgery, MBS) has become a well-established intervention for class III obesity and class II obesity with comorbidities, offering significant and sustained weight loss. The common MBS procedures (eg, Roux-en-Y gastric bypass and sleeve gastrectomy) were indeed found to improve MASLD by ameliorating hepatic steatosis, inflammation, fibrosis, and reducing cancer risk in patients with MASLD/MASH. These effects may go beyond a simple consequence of restricted dietary intake, as illustrated by a growing body of studies showing MBS-induced transcriptional program changes in the liver. Given the mounting evidence from preclinical research, clinical trials, and advanced biotechnologies emerging in recent years, refined histological and cellular in-depth characterization in MBS-treated MASLD is anticipated. This review summarizes the current knowledge on the pathogenic and therapeutic effects of MBS on MASLD, with the hope of inspiring further mechanistic and translational studies.
引用
- Liu H, Lefere S, Guillot A, et al. Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms. Hepatology. 2025. PMID: 40445858. doi:10.1097/HEP.0000000000001417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。